Fundraising Fox
Silver Spur TX
Techstars '25Palos Verdes Peninsula, US · 3 employees on LinkedIn · 1 known investors
Find your way into Silver Spur TX
Silverspurt develops a peptide amphiphile micelle platform for precise, tissue-targeted delivery of small-molecule drugs and genetic therapeutics, reducing systemic toxicity and off-target effects. The platform is designed to improve therapeutic efficacy and patient compliance across multiple therapeutic modalities.
Also known as Silver Spur Therapeutics · Silverspurt
Investors · 1
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · Not right? Tell us
Company profile
researched Sep 2026Silver Spur Therapeutics is a preclinical-stage therapeutics company developing a peptide amphiphile micelle (PAM) nanoparticle platform for the delivery of small-molecule drugs and genetic therapeutics. The company frames its work around a limitation it identifies in conventional therapies: inefficient tissue targeting that requires high or repeated dosing and can result in systemic toxicity, off-target effects and reduced patient compliance.
The platform is engineered to improve biodistribution and tissue-specific targeting, with an initial focus on kidney and cardiovascular diseases, where the stated goal is to deliver therapeutic agents directly to the cellular drivers of disease. The company describes the platform as modular and compatible with both small molecules and RNA therapeutics, and states that preclinical studies have shown tolerability and safety across multiple animal models.
Traction
Activity reported by the company includes presenting at the USC Pre-SPARK Program and being named a finalist in Octane's 2025 High Tech Awards for life sciences in October 2025, a November 2025 publication item on single-dose miR-145 micelles for atherosclerosis, and selection to pitch at the BIO International Convention in 2026. The company states that preclinical studies demonstrate tolerability and safety across multiple animal models.
▸Full profile — market position, technology, go-to-market, history
Market position
The company positions itself in nanomedicine-based drug and gene delivery, differentiating its peptide amphiphile micelle approach from conventional small-molecule and gene therapies that it describes as limited by inefficient tissue targeting and dosing-related toxicity.
Stated points of differentiation are tissue-specific targeting efficacy that reduces off-target exposure, localized therapy for kidney and cardiovascular disease delivered to cellular disease drivers, a modular platform compatible with both small molecules and RNA therapeutics, and a safety profile supported by preclinical animal studies.
Technology
The core technology is a peptide amphiphile micelle (PAM) nanoparticle delivery system designed for precise, tissue-specific delivery of therapeutic payloads while limiting off-target exposure and systemic toxicity. The company positions the platform as modular, supporting both small-molecule drugs and RNA therapeutics, and reports preclinical tolerability and safety data across multiple animal models. Associated work includes research on long-term in vivo therapeutic effects of a single dose of miR-145 micelles in atherosclerosis.
Go-to-market
The platform targets therapeutic applications in kidney and cardiovascular disease, with therapies intended for patients affected by those conditions.
History
The company's leadership comprises CEO Laura Bae, previously with Four Seasons Global Operations and Loansnap; CTO Dr. Yi Huang, described as an inventor and scientist in nanomedicine; and cofounder and CSO Dr. Eun Ji Chung, an associate professor at the University of Southern California working in nanomedicine. Company milestones noted in 2025 include participation in the USC Pre-SPARK Program and finalist status in Octane's High Tech Awards.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 4
by search overlap
Companies competing with Silver Spur TX for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 4
launches, deals, and filingsSilver Spur was selected to pitch at the BIO International Convention 2026.
News/publication item reporting long-term, in vivo therapeutic effects of a single dose of miR-145 micelles for atherosclerosis.
Silver Spur Therapeutics was named a finalist in Octane's 2025 High Tech Awards in the life sciences category.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 3
primary sources listed
- Silver Spur TXsilverspurtx.com · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Silver Spur TX do?
- Silver Spur Therapeutics develops peptide amphiphile micelle nanoparticles for targeted drug and gene delivery in kidney and cardiovascular disease.
- Who are Silver Spur TX's investors?
- Silver Spur TX's investors include Techstars.
- Where is Silver Spur TX headquartered?
- Silver Spur TX is headquartered in Palos Verdes Peninsula, US.